Lessons learned from evolving frameworks in adult glioblastoma.
Mirna Lechpammer1, Abdelkader Mahammedi2, Daniel A Pomeranz Krummel3
1Foundation Medicine, Inc., Cambridge, MA, United States; Department of Biochemistry and Molecular Pharmacology, New York University Grossman School of Medicine, New York, NY, United States.
Molecular subtyping of glioblastoma (GBM) reveals unique alterations for targeted therapies. This approach personalizes treatment for aggressive brain tumors and aids in understanding other neurological disorders.
Area of Science:
- Neuro-oncology
- Genomics
- Molecular biology
Background:
- Glioblastoma (GBM) is an aggressive adult brain tumor with variable progression and treatment response.
- Current classification lacks precision due to diverse underlying molecular alterations.
- Personalized medicine requires detailed molecular subtyping for effective therapeutic strategies.
Approach:
- Investigating unique genetic, epigenetic, and transcriptomic alterations in GBM.
- Developing molecular signatures for precise tumor classification.
- Extrapolating subtyping methodologies to other neurological conditions.
Key Points:
- Morphologically similar GBM tumors exhibit distinct molecular profiles.
- Molecular subtyping enables identification of subtype-specific therapeutic targets.
- Personalized diagnosis and management are crucial for improving GBM patient outcomes.
Conclusions:
- Molecular subtyping is essential for advancing glioblastoma treatment.
- This strategy facilitates the development of targeted therapies.
- The approach holds potential for application in neurodegenerative and neuroproliferative disorders.
More Related Videos
05:45Author Spotlight: Enhanced Generation of Patient-Derived 3D Organoids for Glioblastoma and Glioma
Published on: January 19, 2024
10:58Transposon Mediated Integration of Plasmid DNA into the Subventricular Zone of Neonatal Mice to Generate Novel Models of Glioblastoma
Published on: February 22, 2015